Synchron Secures $200 Million to Develop Nonsurgical Brain-Computer Interface
Synchron raised $200 million in a Series D funding round aimed at expanding its operations and speeding up the commercialization of its nonsurgical brain-computer interface (BCI) designed for people with paralysis.
Funding Details and Investors
- Lead investor: Double Point Ventures
- Participating investors include Arch Ventures, Khosta Ventures, Bezos Expeditions, NTI, Metis, Australian National Reconstruction Fund, T.Rx Capital, Qatar Investment Authority, K5 Global, Protocol Labs, and IQT
- The total capital raised by the New York-based medtech company now amounts to $345 million
Context and Industry Momentum
The investment coincides with increasing momentum in the brain-computer interface sector aimed at helping people with paralysis. For example, Precision Neuroscience recently announced a partnership with SCI Ventures to develop its Layer 7 Cortical Interface.
Precision Neuroscience partnered with SCI Ventures, a fund supported by the Christopher & Dana Reeve Foundation, to advance its Layer 7 Cortical Interface.
Additionally, a recent study showed that Science Corp.’s PRIMA BCI retinal implant partially restored vision for individuals with severe age-related macular degeneration.
Author's Summary
Synchron's substantial funding round highlights growing interest and investment in nonsurgical brain-computer interfaces to improve life quality for people with paralysis.